(PD). 4,6,7,15,17,21,26 Randomized controlled studies have shown that DBS combined with medical therapy provides superior outcomes compared with medical management alone for the control of motor symptoms in advanced disease. 7,33,36 There are currently 3 major DBS targets for managing PD symptoms. While thalamic stimulation is usually reserved for a few patients with tremor-predominant PD, 18,27 subthalamic nucleus (STN) and globus pallidus pars interna (GPi) DBS can treat motor cardinal symptoms of the disease, including tremor, rigidity, and bradykinesia, and manage motor fluctuations.
6Randomized comparisons between GPi and STN DBS showed similar outcomes for both nuclei.9,14,34 Concerns related to higher hemorrhage risk during microelectrode recording-guided GPi DBS surgery 2 can make this a lessfavored target by some centers. However, cognitive and behavioral adverse effects may be more common after STN DBS. 9,34 In our center, we consider patients for both STN and GPi surgery and tailor the target choice to the patient's goals and presentation. Although DBS is effective for symptom management, it does not prevent the progression of the disease. 5,8 We present here the case of a patient in whom bilateral STN DBS was effective, but whose PD progressed with severe motor, particularly dystonic, abbreviatioNs DBS = deep brain stimulation; GPi = globus pallidus pars interna; IPG = implantable pulse generator; LEDD = levodopa equivalent daily dose; MDS-UPDRS = Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale; NRS-11 = 0- to 10-point Numerical Rating Scale; PD = Parkinson's disease; PW = pulse width; STN = subthalamic nucleus. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) or globus pallidus pars interna (GPi) is well established as a treatment for advanced Parkinson's disease. In general, one of the 2 targets is chosen based on the clinical features of each patient. Stimulation of both targets could be viewed as redundant, given that the 2 targets are directly connected. However, it is possible that each target has different mechanisms, with clinical effects mediated by orthodromic or antidromic stimulation. The authors report the case of a patient with severe Parkinson's disease who had previously undergone bilateral subthalamic stimulation with excellent benefits. However, he presented with significant worsening associated with disease progression and pharmacological treatment, and then underwent bilateral GPi DBS. Follow-up assessment was conducted clinically as well as through blinded ratings of video recordings. Pallidal DBS may be a safe and useful strategy to manage dystonic features and behavioral complications of subthalamic stimulation and pharmacological management. While combined stimulation was quite successful in the reported patient, further studies with larger samples and longer follow-up periods will be necessary before recommending the addition of pallidal DBS as a routine strategy for patients previously implanted with STN DBS.